je.st
news
Tag: merck
Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
2016-01-15 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has reached an agreement with plaintiffs to resolve In re Merck & Co., Inc. Securities Litigation, a multi-district class action lawsuit pending in New Jersey federal court. The settlement class consists of persons who purchased Merck securities during the period from May 21, 1999, through Oct. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: related
action
class
previously
Raymond James Trust Buys $13,314,000 in Merck & Co., Inc. (MRK) Shares
2016-01-15 11:40:41| Biotech - Topix.net
Raymond James Trust boosted its stake in shares of Merck & Co., Inc. by 12.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 252,067 shares of the company's stock after buying an additional 28,307 shares during the period.
Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
2016-01-11 22:08:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Acquisition Grows Mercks Oncology Pre-Clinical Pipeline with Novel IDO1 and TDO Inhibitors KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: development
program
pharma
expands
Merck & Co., Inc. (MRK) Shares Sold by Kempner Capital Management
2016-01-10 13:08:33| Biotech - Topix.net
Kempner Capital Management decreased its position in Merck & Co., Inc. by 4.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,768 shares of the company's stock after selling 2,164 shares during the period.
Tags: management
capital
sold
shares
Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
2016-01-08 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 11, 2016 at 3:00 p.m. PST (6:00 p.m. EST). During his presentation, Frazier will provide an update on the state of the company, including accomplishments in 2015 and plans for 2016. Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Steven Cragle, (908) 740-1801orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
annual
conference
morgan
Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] next »